Company intelligence / Profile preview

Aspen Neuroscience

San Diego, California, United Statesaspenneuroscience.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has completed the first two cohorts in its ASPIRO Phase 1/2a trial of ANPD001 in moderate to severe Parkinson's Disease. The primary endpoint is safety and tolerability; so far, no serious adverse events have been observed and all patients were discharged within protocol timelines. Secondary endpoints include improvements in motor symptoms and quality of life. The program now advances to a new commercial formulation.

Therapeutic areas: Neurology
Modalities: Autologous induced pluripotent stem cell (iPSC)-derived cell therapiesGene-corrected autologous neuron therapy (in research)
Industry: Biotech

Drug pipeline

6 assets

autologous neural stem cells

5 more assets in the full pipeline.

Request access →

Partnerships

Cell X Technologies (collaboration and license agreement to automate the iPSC manufacturing process)

Beyond the preview

Go deeper on Aspen Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspen Neuroscience.

Explore the full profile